Given our focus on different WHO grade I tumours, NF2 mutations being the most frequent and the proteomics data indicating two groups within NF2−/− grade 1 meningioma, we decided to pursue further understanding of these two distinct NF2−/− groups and continue validating the highly expressed specific target found up-regulated in NF2−/− meningiomas, ANXA3. This evidence concerns the gene ANXA3 and meningioma.